Levocloperastine Fendizoate: The Better Antitussive Agent Over Codeine

sick-chest-xrayMany of the antitussive agents available in the market today act on the CNS, and cause the adverse events mostly associated with them such as sedation, vomiting, and nausea. One in particular, codeine, can lead to drug dependence. Because of this, pharmaceutical companies were prompted to develop a peripherally-acting antitussive agent that minimizes these central adverse effects. The endeavor resulted in a new research molecule, Levocloperastine Fendizoate CAS# 220329-19-1.

What is levocloperastine fendizoate and how does it work?

Levocloperastine is the levorotatory isomer of DL-cloperastine and fendizoate is its salt. Levocloperastine fendizoate is an antitussive agent that acts both centrally, on the bulbar cough center, and peripherally, on the cough receptors in the tracheobronchial tree. This dual mechanism of action makes levocloperastine fendizoate effective in the treatment of cough associated with many chronic and acute conditions in patients of all ages.

Levocloperastine Fendizoate Supply:

LGM Pharma has been supplying this API to various pharmaceutical companies around the globe who are actively involved in its ongoing research. If you are one of those companies looking to source this material for R&D or compounding purposes, inquire with us about purchasing Levocloperastine Fendizoate CAS# 220329-19-1.

Levocloperastine Fendizoate CAS No 220329-19-1

Clinical Studies:

The past clinical studies on levocloperastine fendizoate demonstrated its superior pharmacological effect over other antitussive agents currently used in cough medications. In 1992, a large-scale clinical trial showed the drug’s antitussive activity to be similar to the opiate agent, codeine.

In 2004, a clinical trial was conducted in Italy by Aliprandi et al., using children and adults as study participants. The majority of the children who participated had acute bronchial inflammatory conditions at the time, while adult subjects had chronic pulmonary disorders. The antitussive effects were observed as early as the first day of treatment, manifested by improved subjective, objective, and laboratory parameters. Objective measurements used in the study included reduction in cough frequency and intensity, nighttime disturbances, and difficulties in expectoration. Laboratory measurements included improvements on cardiovascular and respiratory parameters.

The same study found out that levocloperastine fendizoate exhibited a faster onset of action with a substantial reduction in the intensity and frequency of cough. It was also generally well-tolerated by the body. Unlike codeine, it did not produce the adverse effects associated with the opiate agent such as sedation, dry mouth, nausea, and drug dependence.

Moreover, levocloperastine fendizoate didn’t interact with other drugs which makes it a safe alternative for patients who take medications for other conditions. Given the amount of positive research results, it will only be a matter of time before levocloperastine fendizoate joins the market of antitussive agents currently used in medical practice today.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.